Rare Hematology Market Witness High Revenue Growth, Garnering More Than USD 4 Billion By 2022

DataM Intelligence’s latest market report titled ‘Global Rare Hematology Market - Size, Share and Forecast (2019 - 2026)’ reflects the size, scope, industry dynamics, major firms and future trends in this market. The research report analyses drivers and restraints operating in this competitive space to present a better in-depth of the underlying market opportunities.

Rare Haematology Market Company Trends
The global incidence of hemophilia is not well known, but it is estimated that more than 400,000 people are living with hemophilia A and B.
Approximately 75% of people with hemophilia around the globe still receive inadequate treatment or have no access to treatment. This presents a tremendous market opportunity, thus driving market growth in the future.

Click on the link to get a free sample of the report -https://www.datamintelligence.com/research-report/rare-haematology-market/

Rare Haematology Market Segmentation Analysis
Global Rare Hematology market report segments the market by product class, by indication, by age, and by region.
Based on product class, the market is classified into Recombinant factor, Plasma-derived factors and Extended Half-Life clotting factors.
Recombinant factors segment is projected to witness the highest revenue growth, garnering more than USD 4 billion by 2022.
Based on the indication, the market is segmented into Hemophilia A, Hemophilia A with Inhibitors, Hemophilia B, Acquired Hemophilia A, and von Willebrand disease.
The market is led by Hemophilia A segment.
Based on patient age-group, the market is segmented into adults (18+) and pediatrics (0-17).
Adults account for 75% of the market.

The Rare Haematology market Geographical Analysis
Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
Globally North America is the largest market for Rare Hematology Treatment with the majority of demand arising from the US.
The US hemophilia drug market, which serves about 20,000 patients, is worth USD 4 billion a year.


The Rare Haematology Market Scope of the Report
By Product Class

By Indication

By Patient Age-group

By Region

Read more information about the research report -https://www.datamintelligence.com/research-report/rare-haematology-market/

Table of contents overview -
Chapter 1 – Rare Haematology Market – Methodology and Scope
Chapter 2 – Rare Haematology Market – Trends
Chapter 3 – Rare Haematology Market – Industry Analysis
Chapter 4 – Rare Haemotology Market Analysis
4.1 By Product Class
4.2 By Indication
4.3 By Patient Age-Group
Chapter 5 – Rare Haemotology Market - Geographical Analysis
5.1. North America
5.2. Europe
5.3. Asia Pacific
5.4. South America
5.5 Rest of the World
Chapter 6 – Rare Haemotology Market - Competitive Landscape
Chapter 7 – Rare Haemotology Market - Company Profiles
Chapter 8 – Rare Haemotology Market - Appendix

Corporate Address
1st floor, Phoenix Tech Tower, Plot no: 14/46, Habsidguda, IDA-Uppal, Hyderabad-500039, Telangana

Email
info@datamintelligence.com

Phone
+1 877-441-4866

About DataM Intelligence

DataM Intelligence 4Market Research is a Market Intelligence and Business Research firm, based in India. It aims to bridge the two main aspects of a business decision - opinion and supportive data.

DMI is currently strengthening its cross-industrial database for sectors including Chemicals, Materials, Agriculture, Healthcare Services, Animal Nutrition, Consumer Goods, Food & Beverages, Industrial Machinery and Automation among others.

This release was published on openPR.